IL305530A - Inhibitors of receptor-binding protein 1, their preparations and their uses - Google Patents
Inhibitors of receptor-binding protein 1, their preparations and their usesInfo
- Publication number
- IL305530A IL305530A IL305530A IL30553023A IL305530A IL 305530 A IL305530 A IL 305530A IL 305530 A IL305530 A IL 305530A IL 30553023 A IL30553023 A IL 30553023A IL 305530 A IL305530 A IL 305530A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- tautomer
- pharmaceutically acceptable
- acceptable salt
- deuterated derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021081514 | 2021-03-18 | ||
| PCT/CN2022/081544 WO2022194259A1 (en) | 2021-03-18 | 2022-03-17 | Receptor-interacting protein 1 inhibitors, preparations, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL305530A true IL305530A (en) | 2023-10-01 |
Family
ID=83321909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL305530A IL305530A (en) | 2021-03-18 | 2022-03-17 | Inhibitors of receptor-binding protein 1, their preparations and their uses |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240217963A1 (https=) |
| EP (1) | EP4308555A4 (https=) |
| JP (1) | JP2024512931A (https=) |
| CN (1) | CN117500795A (https=) |
| CA (1) | CA3209628A1 (https=) |
| IL (1) | IL305530A (https=) |
| WO (1) | WO2022194259A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024233544A1 (en) | 2023-05-10 | 2024-11-14 | Genzyme Corporation | Isoxazolidines as ripk1 inhibitors and use thereof |
| CN121487930A (zh) | 2023-05-10 | 2026-02-06 | 建新公司 | 作为ripk1抑制剂的异噁唑烷及其用途 |
| CN121079291A (zh) | 2023-05-10 | 2025-12-05 | 建新公司 | 作为ripk1抑制剂的异噁唑烷及其使用 |
| CN120607513A (zh) * | 2024-03-08 | 2025-09-09 | 山东全重生物医药科技有限公司 | Ripk1抑制剂、其制备方法及其在医药上的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2637620A1 (en) * | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| TW200815426A (en) * | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
| WO2008005368A2 (en) * | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
| ES2404580T3 (es) * | 2007-10-11 | 2013-05-28 | Glaxosmithkline Llc | Novedosos inhibidores de la ehs y uso de los mismos |
| JP2011510996A (ja) * | 2008-01-30 | 2011-04-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| CA2813162C (en) * | 2010-10-20 | 2015-06-16 | Pfizer Inc. | Pyridine-2- derivatives as smoothened receptor modulators |
| HUE039922T2 (hu) * | 2012-12-11 | 2019-02-28 | Takeda Pharmaceuticals Co | Heterociklusos vegyületek |
| WO2016101885A1 (en) * | 2014-12-24 | 2016-06-30 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| EP3224245B1 (en) * | 2014-12-24 | 2018-09-12 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| TWI730959B (zh) * | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| TW201831464A (zh) * | 2016-11-18 | 2018-09-01 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| SG11202105250TA (en) * | 2018-11-20 | 2021-06-29 | Sironax Ltd | Cyclic Ureas |
| CN113272272B (zh) * | 2018-11-20 | 2023-04-07 | 圣瑞诺有限公司 | Rip1抑制剂 |
| KR20200087922A (ko) * | 2019-01-11 | 2020-07-22 | 보로노이바이오 주식회사 | (3-페닐이속사졸리딘-2-일)(피페리딘-4-일)메타논 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
-
2022
- 2022-03-17 CN CN202280022439.7A patent/CN117500795A/zh active Pending
- 2022-03-17 JP JP2023556737A patent/JP2024512931A/ja active Pending
- 2022-03-17 US US18/549,923 patent/US20240217963A1/en active Pending
- 2022-03-17 WO PCT/CN2022/081544 patent/WO2022194259A1/en not_active Ceased
- 2022-03-17 IL IL305530A patent/IL305530A/en unknown
- 2022-03-17 CA CA3209628A patent/CA3209628A1/en active Pending
- 2022-03-17 EP EP22770611.6A patent/EP4308555A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240217963A1 (en) | 2024-07-04 |
| CA3209628A1 (en) | 2022-09-22 |
| EP4308555A1 (en) | 2024-01-24 |
| CN117500795A (zh) | 2024-02-02 |
| JP2024512931A (ja) | 2024-03-21 |
| WO2022194259A1 (en) | 2022-09-22 |
| EP4308555A4 (en) | 2025-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020214404B2 (en) | Immunomodulators, compositions and methods thereof | |
| KR102563325B1 (ko) | Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도 | |
| IL305530A (en) | Inhibitors of receptor-binding protein 1, their preparations and their uses | |
| KR102469161B1 (ko) | Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도 | |
| KR102585860B1 (ko) | Ｒｈｏ-관련 단백질 키나아제 억제제, 이를 포함하는 약학 조성물, 및 이의 제조 방법 및 용도 | |
| AU2011283684B2 (en) | AMPK-activating heterocyclic compounds and methods for using the same | |
| AU2013344049B2 (en) | ALK kinase inhibitors | |
| AU2019211382B2 (en) | Aminopyrrolotriazines as kinase inhibitors | |
| US10022374B2 (en) | Certain protein kinase inhibitors | |
| WO2012171337A1 (en) | Therapeutically active compositions and their methods of use | |
| WO2020011243A1 (en) | Immunomodulators, compositions and methods thereof | |
| KR20160141859A (ko) | 신규 2치환 1,2,4-트리아진 화합물 | |
| JP7604067B2 (ja) | ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途 | |
| CA3225785A1 (en) | Cd38 modulators and methods of use thereof | |
| KR102600391B1 (ko) | 삼중고리형 화합물 | |
| CA3201152A1 (en) | Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors | |
| EP3904348A1 (en) | Aminopyridine compound, preparation method therefor and use thereof | |
| HK40107958A (zh) | 受体相互作用蛋白1抑制剂、其制备及用途 | |
| CN121949300A (zh) | 杂环类化合物、其药物组合物及其用途 | |
| CN117126140A (zh) | 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途 | |
| CN117715898A (zh) | 六元芳基或杂芳基酰胺类化合物及其组合物和用途 | |
| HK40041650A (en) | Tam family kinase /and csf1r kinase inhibitor and use thereof | |
| HK1218119B (en) | Certain protein kinase inhibitors |